🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 23/01/2017 | 81,09 | 81,75 | 80,06 | 81,40 | +0,04% | 2,08% | 1.124.000 |
| 20/01/2017 | 81,47 | 82,46 | 80,89 | 81,37 | +0,57% | 1,93% | 1.105.600 |
| 19/01/2017 | 82,55 | 82,72 | 80,51 | 80,91 | -1,95% | 2,68% | 1.653.000 |
| 18/01/2017 | 81,88 | 82,87 | 81,58 | 82,52 | +1,19% | 1,58% | 1.620.700 |
| 17/01/2017 | 82,35 | 82,55 | 79,78 | 81,55 | -1,95% | 3,36% | 1.501.500 |
| 13/01/2017 | 82,40 | 84,41 | 81,71 | 83,17 | +0,95% | 3,28% | 1.518.600 |
| 12/01/2017 | 81,61 | 82,68 | 80,50 | 82,39 | +0,56% | 2,67% | 1.351.700 |
| 11/01/2017 | 83,17 | 85,37 | 80,38 | 81,93 | -1,21% | 6,00% | 2.785.200 |
| 10/01/2017 | 82,60 | 83,47 | 81,69 | 82,93 | +0,08% | 2,15% | 2.109.700 |
| 09/01/2017 | 79,80 | 83,62 | 77,09 | 82,86 | +4,37% | 8,18% | 4.522.500 |
| 06/01/2017 | 78,94 | 79,70 | 77,56 | 79,39 | +0,42% | 2,71% | 1.669.800 |
| 05/01/2017 | 77,15 | 79,61 | 76,15 | 79,06 | +2,61% | 4,48% | 2.354.700 |
| 04/01/2017 | 75,22 | 78,09 | 74,87 | 77,05 | +2,88% | 4,28% | 1.667.700 |
| 03/01/2017 | 74,43 | 74,99 | 73,34 | 74,89 | +1,66% | 2,22% | 1.761.900 |
| 30/12/2016 | 74,67 | 74,99 | 73,23 | 73,67 | -1,03% | 2,36% | 1.357.400 |
| 29/12/2016 | 74,45 | 75,01 | 73,73 | 74,44 | -0,20% | 1,72% | 938.600 |
| 28/12/2016 | 75,20 | 75,50 | 74,52 | 74,59 | -0,80% | 1,30% | 1.166.000 |
| 27/12/2016 | 74,32 | 76,28 | 74,32 | 75,19 | +1,18% | 2,64% | 1.032.800 |
| 23/12/2016 | 72,11 | 74,81 | 71,96 | 74,31 | +3,18% | 3,95% | 1.485.200 |
| 22/12/2016 | 72,61 | 73,00 | 71,46 | 72,02 | -0,80% | 2,12% | 2.486.200 |
| 21/12/2016 | 76,30 | 76,80 | 72,41 | 72,60 | -5,02% | 5,75% | 2.845.100 |
| 20/12/2016 | 76,44 | 76,85 | 75,97 | 76,44 | +0,18% | 1,15% | 1.327.000 |
| 19/12/2016 | 76,46 | 78,45 | 76,05 | 76,30 | -0,65% | 3,14% | 1.555.100 |
| 16/12/2016 | 77,35 | 78,90 | 76,29 | 76,80 | -0,32% | 3,37% | 2.280.200 |
| 15/12/2016 | 78,00 | 78,62 | 76,27 | 77,05 | -1,63% | 3,01% | 1.972.200 |
| 14/12/2016 | 76,34 | 78,69 | 76,00 | 78,33 | +2,26% | 3,52% | 3.200.100 |
| 13/12/2016 | 76,62 | 77,77 | 76,08 | 76,60 | +0,68% | 2,21% | 1.210.100 |
| 12/12/2016 | 76,58 | 76,92 | 75,24 | 76,08 | -0,77% | 2,19% | 1.731.700 |
| 09/12/2016 | 77,70 | 79,67 | 76,28 | 76,67 | -0,71% | 4,36% | 1.618.500 |
| 08/12/2016 | 75,98 | 77,34 | 74,59 | 77,22 | +2,52% | 3,62% | 1.773.400 |